Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 8, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-08

Reporting Person: venBio Global Strategic Fund II L.P. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series D Preferred Stock	$		Common Stock (6714413)		Direct
Series E Preferred Stock	$		Common Stock (648256)		Direct

Footnotes

F1: The Series D and Series E Preferred Stock are convertible into Common Stock on a 2.133-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2: Robert Adelman and Corey Goodman, the managing partners of venBio Global Strategic Fund II LP ("venBio"), share voting and dispositive control over the shares held by venBio.